What's in GWT-TUD GmbH's pipeline?

GWT-TUD GmbH has 9 drugs in our index: 6 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with GWT-TUD GmbH's portfolio?

Top competitors by shared drug class: Padagis LLC, Stiefel, a GSK Company, Sanofi, B. Braun Medical SA, CD Pharma India Pvt. Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gwt-tud-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

GWT-TUD GmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GWT-TUD GmbH pipeline: 6 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Acnatac® Gel right face	Acnatac® Gel right face	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)	Dermatology
Epiduo® Gel left face	Epiduo® Gel left face	marketed
Epiduo® Gel right face	Epiduo® Gel right face	marketed	Retinoid + peroxide combination	Retinoic acid receptor (adapalene); bacterial cell membrane disruption (benzoyl peroxide)	Dermatology
Acnatac® Gel left face	Acnatac® Gel left face	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)	Dermatology
Secukinumab 300 mg	Secukinumab 300 mg	marketed
pazopanib or guideline conform chemotherapy	pazopanib or guideline conform chemotherapy	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit	Oncology
e.-coli-nissle	e.-coli-nissle	phase 3	Probiotic		Gastroenterology
nicotine acid	nicotine acid	phase 3	lipid-regulating agent	GPR109A	Cardiovascular

Therapeutic area mix

Dermatology · 3
Cardiovascular · 1
Gastroenterology · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Padagis LLC · 2 shared drug classes
Stiefel, a GSK Company · 2 shared drug classes
Sanofi · 2 shared drug classes
B. Braun Medical SA · 1 shared drug class
CD Pharma India Pvt. Ltd. · 1 shared drug class
CHU de Quebec-Universite Laval · 1 shared drug class
Biocodex · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for GWT-TUD GmbH:

Cite this brief

Drug Landscape (2026). GWT-TUD GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gwt-tud-gmbh. Accessed 2026-05-17.